Calcific aortic valve stenosis (CAVS) is a common and life-threatening heart disease and the current treatment options cannot stop or delay its progression. A GWAS on 1009 cases and 1017 ethnically matched controls was combined with a large-scale eQTL mapping study of human aortic valve tissues (n = 233) to identify susceptibility genes for CAVS. Replication was performed in the UK Biobank, including 1391 cases and 352,195 controls. A transcriptome-wide association study (TWAS) reveals PALMD (palmdelphin) as significantly associated with CAVS. The CAVS risk alleles and increasing disease severity are both associated with decreased mRNA expression levels of PALMD in valve tissues. The top variant identified shows a similar effect and strong association with CAVS (P = 1.53 × 10−10) in UK Biobank. The identification of PALMD as a susceptibility gene for CAVS provides insights into the genetic nature of this disease, opens avenues to investigate its etiology and to develop much-needed therapeutic options.
Calcific aortic valve stenosis (CAVS) is the most common valvular heart disease (2% in > 65-year-old individuals)1. It is characterized by a progressive remodeling and calcification of the aortic valve, leading to stenosis and heart failure. There is a long period of disease progression before CAVS becomes severe and symptomatic, which provides a window of opportunity for intervention2. Unfortunately, conventional cardiovascular drugs, such as statins and angiotensin-converting-enzyme inhibitors, are unable to stop or delay the progression of CAVS3,4,5,6. If severe CAVS is left untreated, the survival of affected patients is dramatically shortened following the onset of symptoms7. The only effective treatments available for symptomatic patients with severe CAVS are invasive and costly surgical or transcatheter interventions8. Finding new molecular targets to halt or slow disease progression is an urgent priority9.
Our molecular and genetic understanding of CAVS is currently limited. A strong genetic component is suggested by early-onset forms of the disease, familial aggregation, and genetic epidemiology studies10,11,12,13. A number of susceptibility genes were identified14,15,16,17,18. Genome-wide gene expression studies of normal and stenotic human valves have highlighted biological processes that are involved in CAVS19,20. However, full integration of genome-wide association study (GWAS) results with a large-scale transcriptomic data set in aortic valves has not been performed.
In this study, we combine GWAS and valve expression quantitative trait loci (eQTL) results to identify the molecular drivers of CAVS. The GWAS includes 1009 severe cases of tricuspid CAVS confirmed at surgery and 1017 ethnically matched controls with normal aortic valve that underwent cardiac surgery (QUEBEC-CAVS cohort). In parallel, we perform a large-scale eQTL mapping study on human aortic valve tissues (n = 233), which allows us to undertake a transcriptome-wide association study (TWAS)21 on CAVS. The TWAS identifies PALMD on chromosome 1p21.2 as a candidate causal gene, a finding that we further corroborate by Mendelian randomization and colocalization analyses. We then validate the genetic association on 1p21.2 in UK Biobank and confirm that the discovery consists of a non-coronary artery disease (CAD) gene that is specific to CAVS. This is an important step forward to understand the molecular mechanisms underpinning the heritable risk of CAVS.
GWAS in the QUEBEC-CAVS cohort
Table 1 shows the clinical characteristics of 1009 cases and 1017 controls that passed quality controls (QCs). Mean and standard deviation for age was 71.7 ± 8.3 years and 64% were men. About half (53%) of CAVS cases and the majority of controls (98%) had CAD. The GWAS evaluated 7,732,680 single-nucleotide polymorphisms (SNPs) after imputation. The quantile-quantile plot indicated no inflation of observed test statistics (Supplementary Fig. 1). GWAS results are illustrated in Fig. 1a. No SNP reached genome-wide significance (PGWAS = 5 × 10−8). Eight loci had at least one SNP with PGWAS < 1 × 10−6 (Supplementary Table 1 and Supplementary Fig. 2).
Valve eQTL mapping study
An eQTL mapping study was then conducted in the most disease-relevant tissue to study CAVS, i.e., human aortic valve. Valve eQTLs were calculated in 233 patients that passed QC for genotyping and gene expression. A total of 10,598 independent valve eQTLs were identified at PeQTL < 1 × 10−8 (Supplementary Data 1). Overall, these eQTLs involved 2277 genes/probes significantly associated with one to 41 independent SNPs (r2 < 0.8) (Supplementary Fig. 3a). On average, a single SNP explained 26.5% of the gene/probe expression variance. However, 29.1% of the eQTL-SNPs explained more than 30% of the expression variance (Supplementary Fig. 3b).
Identification of PALMD by TWAS
A TWAS21 was then performed using the GWAS and valve eQTL data sets. A Manhattan plot showing transcriptome-wide association in valve tissue with CAVS is shown in Fig. 1b. Only one probe-CAVS association corresponding to the PALMD gene reached genome-wide significance (PTWAS = 0.00007). PALMD is located on chromosome 1p21.2 and the top GWAS SNPs were the same as the top valve eQTL-SNPs (Fig. 2a). rs6702619, a genotyped variant, was the SNP in this locus most significantly associated with both CAVS (odds ratio (OR) = 1.29, 95% confidence interval (CI) 1.14–1.46, PGWAS = 6.12 × 10−5) and the expression of PALMD (PeQTL = 5.82 × 10−33). In addition, formal Bayesian colocalization22 revealed a posterior probability of shared signals (PP4) of 0.96, which confirms that the GWAS and valve eQTL signals share the same variants at the PALMD locus. rs6702619 is located 65.2 kb from the transcriptional start site of PALMD. The valve eQTL rs6702619-PALMD indicated that the risk allele for CAVS (“G”) is associated with lower mRNA expression levels of PALMD in valve tissues (Fig. 2b), suggesting that lower expression increases the risk of CAVS. Variants located within 1 Mb of PALMD that increased its expression tended to decrease the risk of CAVS (Fig. 2c). Concordantly, protein expression of PALMD in aortic valves was lowered in homozygotes GG compared to homozygotes TT for rs6702619 (Supplementary Fig. 4). rs6702619 is a common SNP (minor allele frequency of 47.7% in Europeans from the 1000 Genomes Project) and the estimated population-attributable risk indicates that more than 12.5% of cases in our population could be attributed to this common variant.
Genetically lowered PALMD expression is associated with CAVS
A Mendelian randomization analysis suggested a causal role of lower PALMD expression on CAVS risk, without evidence of pleiotropy. Variants located within 200 kb of PALMD and associated with PALMD gene expression were selected using stepwise regression (Supplementary Table 2) to create an instrument for Mendelian randomization analyses. Effect on PALMD gene expression was inversely associated with the effect on CAVS risk without evidence of pleiotropy (P = 0.0036; Egger intercept P = 0.25; Fig. 3a). The direction of the association was the same when only the lead variant (rs6702619) was included (P = 1.37 × 10−4). Considering the number of tests performed, none of the SNPs in the instrument was significantly associated with the expression of the three nearest genes (PLPPR4, FRRS1, and AGL; P > 0.0042 or 0.05/12). Together, these results indicated that risk variants on 1p21.2 confer susceptibility to CAVS through downregulation of PALMD in aortic valve tissues. The relationship between PALMD expression levels and CAVS severity was also consistent with this direction of effect. Lower normalized, age- and sex-adjusted PALMD expression was associated with smaller aortic valve area (P = 0.0027), higher mean transvalvular gradient (P = 0.0001), and higher peak transvalvular gradient (P = 8.13 × 10−5; Fig. 4).
PALMD eQTL in Genotype-Tissue Expression
We additionally looked for PALMD eQTL in the Genotype-Tissue Expression (GTEx) data set23. rs6702619-PALMD association was not significant in 44 tissues from GTEx, suggesting that the change in expression is specific to aortic valve tissue. Evaluating other SNPs within or near PALMD revealed significant eQTL with this gene in the pancreas, tibial nerve, and subcutaneous adipose tissue. However, these eQTL-SNPs were not in linkage disequilibrium (LD) with CAVS-associated variants.
Replication in UK Biobank
We then replicated our newly associated locus using data recently released by the UK Biobank, which included 1391 CAVS cases and 352,195 unaffected individuals all of European ancestry. We observed a very strong association with an almost identical effect on CAVS risk for our top SNP rs6702619 with an OR of 1.27 (95% CI 1.18–1.37; Fig. 5a). The association was also replicated for rs7543130, a genotyped variant in perfect LD with rs6702619. At the genome-wide scale level, only two loci were genome-wide significant in UK Biobank (Fig. 5b): LPA on 6q25.3-q26 previously associated with aortic valve calcification17; and PALMD on 1p21.2 identified in this study. Mendelian randomization using the effect on CAVS risk as estimated in the UK Biobank also pinpoints PALMD expression as a causal factor (P = 1.18 × 10−5; Egger intercept P = 0.10; Fig. 3b). In UK Biobank, the population-attributable risk for rs6702619 was estimated at 12.3%.
CAVS is a common and life-threatening heart disease with no drug that can stop or delay its progression. Elucidating the genetic factors underpinning CAVS is an urgent priority to find new therapeutic targets9. Major landmarks in genetics of CAVS include the discoveries of NOTCH124 and LPA17. However, genetic variants in these genes accounted for a small number of cases and a low population-attributable risk. Here we mapped a new susceptibility locus for CAVS on chromosome 1p21.2 and identified PALMD (palmdelphin) as the candidate causal gene. PALMD was revealed using a TWAS21, which combined a GWAS of 1009 cases and 1017 ethnically matched controls with the first large-scale QTL mapping study on human aortic valve tissues (n = 233). The CAVS risk alleles and increasing disease severity were both associated with lowered mRNA expression levels of PALMD in valve tissues. The top variant explained up to 12.5% of the population-attributable risk and showed similar effect and strong association with CAVS (P = 1.53 × 10−10) in UK Biobank comparing 1391 cases and 352,195 controls. The identification of PALMD as a susceptibility gene for CAVS provides new insights about the genetic nature of this disease and opens new avenues to investigate its etiology and develop much-needed therapeutic options.
The top GWAS SNP in this study (rs6702619) was recently identified by the EchoGen consortium to be associated with aortic root diameter in a large GWAS meta-analysis, including up to 46,533 individuals25. In our study, rs6702619 was not associated with aortic root diameter (P = 0.18), which was available in a subgroup of 900 participants (698 cases and 202 controls). The EchoGen consortium also identified a SNP in CACNA1C (calcium channel, voltage-dependent, l type, alpha 1C subunit) associated with aortic root diameter25, which we recently identified as a susceptibility gene of CAVS18. As indicated in the later study, rs6702619 is located within enhancer histone marks and DNase-hypersensitive sites in Encyclopedia of DNA Elements (ENCODE) data26. However, rs6702619 was not found to act as cis-eQTL in whole blood, monocytes, and myocardial tissue25. In this study, we found PALMD consistently expressed in human aortic valve tissues and rs6702619 strongly associated with mRNA expression levels of PALMD, providing a potential functional mechanism of how genetic variants on 1p21.2 may increase CAVS susceptibility. Furthermore, a Mendelian randomization analysis suggested that PALMD expression is causally associated with the risk of CAVS.
The frequency of rs6702619 is high in our French Canadian population (minor allele frequency (MAF) = 47%) and the modest effect size (OR = 1.29) is consistent with those observed for other complex traits. The estimated population-attributable risk indicates that more than 12.5% of cases in our population and 12.3% of cases in UK Biobank could be attributed to this common variant. Of note, the frequency of rs6702619 varies greatly between ethnic groups (Supplementary Fig. 5). In the 1000 Genomes Project, allele “G” had a frequency of 48% in Europeans, 8% in Africans, 7% in East Asians, and 25% in South Asians. This may explain some of the discrepancy in risk of CAVS among ethnic groups27,28.
PALMD is a distant homolog of a small paralemmin protein family29. PALMD is expressed in many tissues, but most abundantly in cardiac and skeletal muscle30. It is a mainly cytosolic protein, localized predominantly in actin filaments, and may be implicated in plasma membrane dynamics and cell shape control as other members of this family29,31. However, its molecular and cellular functions remain largely unknown. PALMD was recently shown to promote myoblast differentiation and muscle regeneration32. Considering the common embryologic origin of the aortic valve and the aortic root, which both arise from the secondary heart field, a potential role on smooth muscle and valve interstitial cell differentiation could explain the association with the two phenotypes33,34. PALMD was also identified as a pro-apoptotic gene induced by p53 in response to DNA damage in osteosarcoma cell lines35. However, its role in cell death was not confirmed in other cell types32.
The controls for the QUEBEC-CAVS GWAS were patients with CAD without valvulopathy. This strategy limited our ability to detect shared genetic variants with CAD. On the other hand, genes that are specific for CAVS are more likely to be found. This is illustrated by comparing the LPA locus (a known locus associated with both CAD and CAVS) and the PALMD locus in the UK Biobank with and without adjustment for CAD. The association with CAVS was not influenced at the PALMD locus with an OR = 1.29 (P = 1.02 × 10−10) and OR = 1.27 (P = 6.29 × 10−11) with and without adjustment for CAD, respectively. In contrast, the strength of association at the LPA locus was lowered after adjustment for CAD (OR = 1.39, P = 3.54 × 10−8 vs. OR = 1.56, P = 2.58 × 10−14). The variant identified at the PALMD locus is therefore expected to act via pathways not involved in the risk of CAD. rs6702619 was indeed not associated with CAD in a recent large GWAS meta-analysis (P = 0.96)36. In the QUEBEC-CAVS cohort, the association of rs6702619 with CAVS stratified by the presence of CAD in cases showed consistent results with overlapping effect sizes. In addition, the association of the variant with the presence of CAD in CAVS cases was not significant (P = 0.15). Of note, rs6702619 was not associated with aortic valve calcification measured by computed tomographic scanning in a large GWAS, including 6942 individuals of European ancestry (P = 0.557)17. This suggests that calcification is not the main mechanism by which PALMD expression modulates CAVS progression and could rather appear only in later stages of the disease.
Our study has some limitations. First, only individuals of European ancestry were included in the analysis, therefore results cannot be generalized to other ethnic groups. Second, the power in our GWAS analysis was limited by the number of available samples. However, expression data on the most disease-relevant tissue and replication in a large population-based cohort confirmed the robustness of the findings. Third, aortic valve tissue was only available in stenotic valves; patterns of expression of PALMD in normal valves might differ.
In conclusion, using a TWAS approach with expression data in aortic valve tissue, we identified a new CAVS susceptibility gene, PALMD, with replication in a large prospective population-based cohort. Further analyses of gene expression in valve tissue and disease severity suggested that the identified variant acts by decreasing the expression of PALMD, a finding supported by Mendelian randomization. Further studies are warranted to elucidate the exact mechanism of action and evaluate the potential for targeted therapeutic interventions.
Blood samples and aortic valves were collected from patients with severe aortic valve stenosis undergoing aortic valve replacement at the Institut universitaire de cardiologie et de pneumologie de Québec (QUEBEC-CAVS). Only cases with tricuspid nonrheumatic CAVS were included. No severe regurgitation or other severe valvular heart diseases were present. In parallel, an ethnically matched control group was recruited from patients that underwent cardiac surgery, mostly for isolated coronary artery bypass (> 98%). Other indications for surgery in the control group included heart transplant, tumor removal, aortic endoprosthesis, and interatrial communication. Absence of CAVS was confirmed by echocardiography. This cohort of control patients was also matched in a 1:1 ratio with cases for age, gender, type 2 diabetes, and hypertension. Patients with a history of severe valvular heart disease (at any of the four valves), with significant aortic valve regurgitation (grade > 2) or with end-stage renal disease (estimated glomerular filtration rate < 15 mL/min/1.73 m2) were excluded. CAVS patients and controls were free of congenital heart defects (including bicuspid aortic valve), except for seven participants with interatrial communication (three cases and four controls). All patients signed an informed consent for the realization of genetic studies. The study was approved by the ethics committee of the Institut universitaire de cardiologie et de pneumologie de Québec. Demographics, anthropometric measurements, lifestyle factors, previous and current medical history, current medication, and blood pressure measurements were collected. Having a history of myocardial infarction, coronary artery stenosis on coronary angiography, or documented myocardial ischemia was defined as CAD. In addition, fasting plasma lipids and creatinine were measured. CAVS cases underwent a comprehensive Doppler echocardiographic examination. The transvalvular gradient was calculated using the modified Bernoulli equation and the aortic valve area calculated with the continuity equation. For this study, 1033 cases and 1037 controls were available.
Genome-wide association study
Blood samples were collected and DNA was extracted from frozen buffy coat. Whole-genome genotyping was performed using the Illumina HumanOmniExpress BeadChip. Standard genotyping QCs were performed. SNP genotyping data were filtered for call rate < 97%, low-quality loci with 10th percentile of Illumina GenCall score ≤ 0.1, Hardy-Weinberg equilibrium P < 1 × 10−7, MAF < 1%, and different call rate between cases and controls (P < 1 × 10−6). A total of 613,862 SNPs passed QC checks. Samples were excluded after consideration for the 10th percentile of Illumina GenCall score ≤ 0.2, genotype completion rate < 95%, outlier heterozygosity rate (F > 0.20), genotypic and phenotypic gender mismatch, genetic background outliers detected by principal component analysis with HapMap subjects as population reference panel, and unexpected duplicates and genetic relatedness (first-degree relatives) evaluated by identity-by-state using PLINK37. After the QC filters, 1009 cases and 1017 controls were available for subsequent analyses. Supplementary Tables 3 and 4 provide a summary of genotyping QCs on SNPs and samples. Genotypes were then imputed with the Michigan Imputation Server38 using the Haplotype Reference Consortium version 1 (HRC.r1-1) data39 as reference set (2016-03-31). Variants with an r2 value of ≤ 0.3 or MAF < 1% were removed from further analysis. A total of 7,732,680 imputed SNPs passed QC. Genetic association tests were performed using additive logistic regression models based on expected genotype counts (dosages) as implemented in the software SNPTEST v2.5.2 40, adjusting for age, sex, and the first 10 ancestry-based principal components. The genomic inflation factor for the main case–control analysis was 1.03. The genome-wide significant P value cutoff was set to 5 × 10−8. Regional plots were created with LocusZoom41.
Genetic refinement and population-attributable risk
The association between the lead SNP identified (rs6702619) and CAVS was evaluated with stratified analyses according to the presence of CAD in the case group. We also evaluated the association of this variant with the presence of CAD in the case group. The association between rs6702619 and aortic root diameter measured by ultrasound was evaluated in a subset of 900 participants (698 cases and 202 controls) for which this information was available. We performed linear regression with adjustment for age, sex, body surface area (using the DuBois and DuBois formula), and the first 10 principal components. The population-attributable risk was calculated as PAR% = 100% × P × (OR − 1)/[P × (OR − 1) + 1], where P is the frequency of the risk allele associated with CAVS in the control group, and OR is the odds ratio calculated in the case–control cohort.
Human aortic valve gene expression analysis
Transcriptomic analyses were performed from 240 stenotic aortic valves collected as mentioned above. All stenotic valves were tricuspid and had a fibro-calcific remodeling score of 3 or 442. Selected valves were from cases that are part of the GWAS and included 120 men and 120 women. RNA was extracted from valve leaflets, and gene expression was measured using the Illumina HumanHT-12 v4 Expression BeadChip. Standard microarray processing and QC analysis was performed43. The raw data were quantile normalized after log2-transformation with the lumi package in R44. Only one sample failed QC, leaving 239 samples for subsequent analyses. Probe sequences were mapped to RefSeq B38, GENCODE v24 B38, mRNA B38, and the human genome (GRCh B38) using Bowtie, and probes not mapping to any coding region were removed. A total of 45,699 probes remained after this step. Robust fitting of linear models function (rlm) in the R statistical package MASS was used to adjust gene expression data for age and sex. Residual values were then filtered out if deviating by more than three standard deviations from the median.
Expression quantitative trait loci
Only subjects that passed genotyping and gene expression QCs were considered for eQTL analysis, leaving a sample size of 233. eQTLs were identified by using linear regression model and additive genotype effects as implemented in the Matrix eQTL package in R45. Cis-eQTLs were defined by a 2 Mb window, i.e., 1 Mb distance on either side of the SNP. eQTLs were calculated on adjusted expression traits to obtain test statistics, P values, and false discovery rate. Estimates of effect sizes were obtained with PLINK.
Transcriptome-wide association study
The TWAS was performed using FUSION21. Briefly, the valve eQTL was the reference data, including 233 individuals that passed QC for both gene expression and genotyping. This reference set was used to calculate gene expression weights using prediction models implemented in FUSION. This includes top1 (i.e., the single most significant valve eQTL-SNP as the predictor), LASSO regression, and enet (elastic net regression). SNP data located 500 kb on both sides of the probes were used to obtain expression weights. All probes that passed QC in the valve eQTL were evaluated (n = 45,699). Expression weights were then combined with summary-level GWAS results to estimate association statistics between gene expression and CAVS. Genome-wide significant TWAS genes were considered at PTWAS < 0.0001.
Summary statistics (regression coefficients and variance) from the QUEBEC-CAVS GWAS and valve eQTL results were combined using the COLOC package in R (version 2.3–6)22. COLOC tested for five hypotheses: H0, no eQTL and no GWAS association; H1, association with eQTL, but no GWAS; H2, association with GWAS, but no eQTL; H3, eQTL and GWAS association, but independent signals; and H4, shared eQTL and GWAS associations. The main interest is to assess whether the GWAS and eQTL signals are consistent with shared causal variants (i.e., H4). The result of this procedure is five posterior probabilities (PP0, PP1, PP2, PP3, and PP4). In practice, a high posterior probability (PP4 > 75%) indicates that the GWAS and eQTL signals colocalize.
We first selected variants located within 200 kb of the gene of interest identified in the TWAS, PALMD, and significantly associated with PALMD gene expression at a threshold of P < 0.05.
We then performed stepwise regression (bidirectional elimination) using the step function in R to select SNPs independently associated with PALMD expression (based on the Akaike information criterion). Mendelian randomization was performed using the Wald method by regressing genetic effect estimates for CAVS risk as determined in the GWAS analysis (dependent variable) on genetic effect estimates for PALMD gene expression as determined in the eQTL analysis. Effect estimates were adjusted for the minor allele frequency of each variant (beta × (2 × MAF × (1 − MAF))0.5) to better reflect the variance explained by each variant46,47. To determine the significance of the association, a bootstrap method was used. Predicted effects on CAVS risk and PALMD gene expression were sampled from a normal distribution with mean and standard deviation as determined from the GWAS and eQTL analyses. A two-tailed P value was calculated using 100,000 random simulations. To determine the presence of unmeasured net pleiotropy, we performed Egger Mendelian randomization in which a non-zero y-intercept is allowed in order to assess violations of standard Mendelian randomization48. A P value below 0.05 was considered as significant. A similar analysis was performed using the effect on CAVS risk as estimated in the UK Biobank. We verified the effect of the selected SNPs on the expression of the genes located nearby PALMD: PLPPR4; FRRS1; and AGL by performing linear regression analyses.
Gene expression according to severity
CAVS disease severity was assessed by aortic valve area, mean, and peak transvalvular gradients. The influence of normalized, age- and sex-adjusted PALMD expression levels on disease severity was tested in 239 cases using linear regression models. The 95% confidence intervals were estimated using the predict function in R.
Replication in UK Biobank cohort
UK Biobank is a large prospective cohort of about 500,000 individuals between 40 and 69 years old recruited from 2006 to 2010 in several centers located in the United Kingdom49. The present analyses were conducted under UK Biobank data application number 25205. We used genotyping data obtained from the second genetic data release, including 488,377 individuals. Samples were genotyped with the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom Array. Phasing and imputation were performed centrally using a reference panel combining the Haplotype Reference Consortium (HRC) as a first choice and UK10k and 1000 Genomes Phase 3 samples for SNPs not available in HRC. Samples with call rate < 95%, outlier heterozygosity rate, gender mismatch, non-white British ancestry, related samples (second degree or closer), samples with excess third-degree relatives (> 10), or not used for relatedness calculation were excluded. Variants not on both arrays, which failed QC in more than one batch, with call rate < 95% or with minor allele frequency < 0.0001 were excluded.
CAVS diagnosis was established from hospital record, using the International Classification of Diseases version-10 (ICD10) and Office of Population Censuses and Surveys Classification of Interventions and Procedures (OPCS-4) coding. ICD10 code number I35.0 and OPCS-4 code number K26 were used. Participants with a history of rheumatic fever or rheumatic heart disease as determined by ICD10 codes I00–I02 and I05–I09 were excluded.
We performed additive logistic regression analysis using SNPTEST v2.5.2, adjusting for age, sex, and the first 10 ancestry-based principal components to evaluate the effect of the top SNP identified in our TWAS analysis. We then performed a fixed-effect meta-analysis using the inverse-variance weighted method as implemented in rmeta package version 2.16 in R. To look for other significant variants associated with CAVS in UK Biobank, we performed a GWAS from the genotyped data using additive logistic regression models in PLINK adjusting for age, sex, and the first 10 principal components. The genomic inflation factor for the main case–control analysis was 1.01. The genome-wide significant P value cutoff was set to 5 × 10−8.
Genetic associations at the PALMD and LPA loci were also performed with and without adjustment for CAD. CAD diagnoses were established from ICD10 code numbers I20, I21, I22, I23, I24, and I25, as well as OPCS-4 code numbers K49, K502, K75, K40, K41, K45, and K46. Overall, 25,167 CAD cases were identified. In the main CAVS case–control analysis, CAD was observed in 60% of CAVS cases and 7% of controls.
Statistical analyses were performed with R version 3.2.3 unless otherwise specified. Two-sided P values below 0.05 were considered significant unless otherwise specified.
Mineralized aortic valves were selected according to the genotype at rs6702619 (TT vs. GG). Tissues were mixed with lysis buffer (150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol, 5 mM EGTA, 0.5 mM EDTA, 2 mM sodium vanadate, 50 mM sodium fluoride, 1% Triton X-100, 0.1% SDS, 80 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). Mechanical lysis was performed by using a bead mill homogenizer (VWR, PA, USA), followed by centrifugation at 5000 × g for 12 min at 4 °C. Supernatants were harvested and protein loading buffer (62.5 mM Tris (pH 6.8), 10% glycerol, 2% SDS, and 5% β-mercaptoethanol in H2O) was added. Samples were boiled for 5 min, loaded onto polyacrylamide gels, and separated by electrophoresis, followed by transfer onto nitrocellulose membranes. Membranes were blocked with Tris-buffered saline (TBS)-Tween (5% fat-free milk), according to the manufacturer’s instructions, incubated with either PALMD (Novus Biologicals, ON, Canada, #cat NBP1-88481, dilution 1:500) or GAPDH (Santa Cruz Biotechnologies, TX, USA, #cat sc-25778, dilution 1:1000) primary polyclonal antibodies overnight at 4 °C. After washing in TBS-Tween, membranes were incubated with horseradish peroxidase-labeled secondary antibodies (TransBionovo Co., Ltd, Beijing, China, #cat HS101, dilution 1:2000) and bands were detected using the clarity western ECL substrate (BioRad, ON, Canada). Images were acquired and quantified with the ChemiDocMP system (BioRad).
The genome-wide association summary statistics are available in the database of Genotypes and Phenotypes (dbGaP) under accession phs001492.v1.p1. The microarray gene expression data set on human aortic valves was deposited in Gene Expression Omnibus with accession number GSE102249. All valve cis-eQTLs identified are listed in Supplementary Data 1.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We thank the research team at the cardiac surgical database and biobank of the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) for their valuable assistance. This research has been conducted using the UK Biobank Resource. P.P. holds the Canada Research Chair in Valvular Heart Disease and his research program is supported by a Foundation Scheme Grant from Canadian Institutes of Health Research (Ottawa, Ontario, Canada). P.M. holds a Fonds de Recherche du Québec-Santé (FRQS) Research Chair on the Pathobiology of Calcific Aortic Valve Disease. Y.B. holds a Canada Research Chair in Genomics of Heart and Lung Diseases. This work was supported by the Heart and Stroke Foundation of Canada and the Canadian Institutes of Health Research [MOP - 102481, MOP – 137058, PJT - 153396] to Y.B.